Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 6/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28237494 | 0.89 | DPP4 (0.42) | DPP4PNPPDPK1GDACDK2 | |
| SCHEMBL2385930 | 0.88 | ADORA2B (0.50) | DPP4PNPPDPK1GDACDK2 | |
| SCHEMBL9806974 | 0.87 | PNP (0.44) | DPP4PNPPDPK1GDACDK2 | |
| SCHEMBL6751932 | 0.85 | PNP (0.43) | DPP4PNPPDPK1GDACDK2 | |
| SCHEMBL29174358 | 0.82 | PNP (0.45) | DPP4PNPPDPK1GDACDK2 | |
| SCHEMBL6266585 | 0.81 | CDK1 (0.40) | PNPPDPK1GDACDK2CDK1 | |
| SCHEMBL15743135 | 0.80 | CDK1 (0.42) | DPP4PNPPDPK1GDACDK2 | |
| SCHEMBL6952184 | 0.80 | SLC2A1 (0.41) | PNPPDPK1GDACDK2CDK1 | |
| SCHEMBL28460015 | 0.78 | CDK2 (0.38) | PNPPDPK1GDACDK2CDK1 | |
| SCHEMBL27617652 | 0.77 | PNP (0.44) | PNPCDK2CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20200109362-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-09 | — | — | US | disclosed |
| CN-107903267-B | Azo aromatic nitrogen mustard-chloroethyl nitrosourea coupled compound, preparation method and application | 北京工业大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-108484604-B | Azo aromatic nitrogen oxide-chloroethyl nitrosourea coupling molecule targeting tumor hypoxia, and preparation method and application thereof | 北京工业大学 | 2020-01-17 | — | — | CN | disclosed |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DELMAR PHARMACEUTICALS INC (CA) | 2018-05-31 | — | — | US | disclosed |
| CN-107903267-A | A kind of compound and preparation method and application of the coupling of azo aryl nitrogen mustard chlorethylnitrosourea | 北京工业大学 | 2018-04-13 | — | — | CN | disclosed |
| US-9901563-B2 | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol | DELMAR PHARMACEUTICALS, INC. (CA) | 2018-02-27 | — | — | US | disclosed |
| CN-107722010-A | A kind of hypoxemia activation chlorethylnitrosourea containing nitroimidazole group and its preparation method and application | 北京工业大学 | 2018-02-23 | — | — | CN | disclosed |
| WO-2017223254-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-28 | — | — | WO | disclosed |
| CN-105503874-B | Hypoxemia activates joint chloroethylnitrosoureas compound and preparation method and application | 北京工业大学 | 2017-10-27 | — | — | CN | disclosed |
| EP-0702683-B8 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6635677-B2 | Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea | CASE WESTERN RESERVE UNIVERSITY | 2003-10-21 | — | — | US | disclosed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020198264-A1 | Methoxyamine combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2002-12-26 | — | — | US | disclosed |
| US-6465448-B1 | TREATING TUMORS RESISTANT TO TEMOZOLOMIDE ALONE | CASE WESTERN RESERVE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| WO-2001012199-A2 | METHOXYAMINE POTENTIATION OF TEMOZOLOMIDE ANTI-CANCER ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0702683-A1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | DPP4 3598/4885PNP 1267/4885PDPK1 921/4885 |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DDOST, DAD1, B3GAT3 | DPP4 442/4885PNP 1702/4885PDPK1 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.